Our discovery starts with patient data powered by AI. Using the unique RNA signature of each patient, we build Living Molecular Twins, digital twins of patients’ biological networks using systems biology and our proprietary foundation model of human health. No data? We developed a home collection kit for RNAseq, which we have deployed globally to patients across >100 disorders using our rareSHIFT discovery program.

We rapidly identify new therapeutic mechanisms regardless of root cause of the disease and use our proprietary database to specify molecules to restore health without needing to know a drug target first. If needed, we build animal models in a matter of weeks to ask clinically relevant questions about efficacy and safety. Patients can’t wait for decades of basic research.

We clinically derisk discovered therapeutic mechanisms in real patients using the off-target effects of existing drugs, letting us clinically validate the therapeutic impact of new biology incredibly quickly and efficiently. By prototyping in partnership with patients before committing to new molecule development, we can more quickly and inexpensively discover what truly works: in patients, not models. This helps patients today, while derisking new therapeutics we develop in parallel. We have enabled clinicians to achieve clinical efficacy in 100% of the patients we analyzed.